Elevated soluble urokinase plasminogen activator receptor (suPAR) in COVID-19 patients

Giuseppe Lippi; Brandon M. Henry; Emmanuel J. Favaloro

doi:10.1515/cclm-2021-0561

Elevated soluble urokinase plasminogen activator receptor (suPAR) in COVID-19 patients

Giuseppe Lippi, Brandon M. Henry, Emmanuel J. Favaloro

Nursing, Paramedicine and Healthcare Sciences

Research output: Contribution to journal › Letter › peer-review

9 Citations (Scopus)

6 Downloads (Pure)

Abstract

Original language	English
Pages (from-to)	E413-E415
Number of pages	3
Journal	Clinical Chemistry and Laboratory Medicine
Volume	59
Issue number	11
Early online date	14 Jun 2021
DOIs	https://doi.org/10.1515/cclm-2021-0561
Publication status	Published - Oct 2021

Access to Document

10.1515/cclm-2021-0561

167831730 published articleFinal published version, 219 KB

Cite this

@article{f5c2c52fc7454b9ba35e2aa3d4e26e61,

title = "Elevated soluble urokinase plasminogen activator receptor (suPAR) in COVID-19 patients",

keywords = "coronavirus, COVID-19, soluble urokinase plasminogen activator receptor, suPAR",

author = "Giuseppe Lippi and Henry, {Brandon M.} and Favaloro, {Emmanuel J.}",

year = "2021",

month = oct,

doi = "10.1515/cclm-2021-0561",

language = "English",

volume = "59",

pages = "E413--E415",

journal = "Clinical Chemistry and Laboratory Medicine",

issn = "1437-4331",

publisher = "Walter de Gruyter GmbH",

number = "11",

}

TY - JOUR

T1 - Elevated soluble urokinase plasminogen activator receptor (suPAR) in COVID-19 patients

AU - Lippi, Giuseppe

AU - Henry, Brandon M.

AU - Favaloro, Emmanuel J.

PY - 2021/10

Y1 - 2021/10

KW - coronavirus

KW - COVID-19

KW - soluble urokinase plasminogen activator receptor

KW - suPAR

U2 - 10.1515/cclm-2021-0561

DO - 10.1515/cclm-2021-0561

M3 - Letter

C2 - 34116589

SN - 1437-4331

VL - 59

SP - E413-E415

JO - Clinical Chemistry and Laboratory Medicine

JF - Clinical Chemistry and Laboratory Medicine

IS - 11

ER -